Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore- mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC.在此敘述一種衍生自序列識別號:42及其片段之單離胜肽,其結合於HLA抗原並誘導細胞毒性T淋巴球(CTL),因此適用於癌症免疫療法,具體為癌症疫苗。本發明胜肽包括上述胺基酸序列及其經修飾者,其中有1、2或數個胺基酸序列經取代、刪除、加成或插入,但這些經修飾的胺基酸序列保留該原始序列必要的HLA結合及CTL誘導能力。又,更提供編碼上述任一胜肽的核酸,及包括或含有上述任一胜肽或核酸的醫藥藥劑、物質及/或組合物。本發明的胜肽、核酸、醫藥藥劑、物質及組合物特別用於治療癌症及腫瘤,包括例如膀胱癌、乳癌、子宮頸癌、膽管細胞癌、CML、大腸直腸癌、食道癌、NSCLC、淋巴癌、胰臟癌、前列腺癌、腎癌及SCLC。
